ICICI Securities maintains an Add call on Apollo Hospitals Enterprise, raising the target price to Rs 7,500. This revision reflects anticipated faster growth and improved margins in the pharmacy sector. The brokerage has increased revenue, EBITDA, and PAT estimates for FY26 and FY27, valuing the hospital business at 25x FY27E EV/EBITDA.
Market in consolidation mode; triggers needed, says Sunil Subramaniam
Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled